The consensus on Regeneron in early 2023 is that it is a diversified antibody powerhouse. The single fact that undercuts the comfort is in the company's own annual report: it describes itself as substantially dependent on the success of two products.
In its Form 10-K filed February 6, 2023, Regeneron states it is substantially dependent on the success of Eylea and Dupixent, and that Eylea net sales represent a substantial portion of its revenues — a concentration the company explicitly flags as a risk. When a company writes that sentence about itself under securities law, it is not hedging; it is warning.
Define the cliff plainly. Eylea is an eye-disease drug — an injection for conditions like wet age-related macular degeneration. “Exclusivity cliff” means the period when patent and regulatory protections that keep competitors out begin to lapse, opening the door to biosimilar or next-generation rivals. The more revenue rides on one such product, the steeper the cliff if competition arrives.
Acknowledge the bull case before dismantling it. Regeneron's R&D engine is genuinely deep, and Dupixent is a large second pillar. But the 10-K is the company's own admission that a single eye drug carries a substantial portion of the top line. Diversification that depends on two products is less diversification than the narrative implies.
Read the risk factors and the math is simple: the higher the share of revenue concentrated in Eylea, the more any erosion of its exclusivity matters. As of this filing, the company is telling investors to watch that concentration. The cliff is a question of when competition bites, and the exposure is disclosed in black and white.
The EdgarBeast evidence index, which surfaces and normalizes SEC filings, lets you find the exact sentence where a company concedes its own concentration risk. For Regeneron in early 2023, that sentence is plain: substantially dependent on Eylea and Dupixent. That dependence is the cliff to watch.